Williams-Sonoma’s (NYSE: WSM) stock broke out of a trading range earlier this year to confirm its uptrend remains intact. The market reconfirmed the breakout following the Q2 earnings release, signaling the next leg of the uptrend is at hand. How high the stock gets depends on several factors, incl.... |
Good MorningU.S. stocks edged lower Wednesday as a slightly hotter-than-expected headline PCE inflation reading renewed pressure on rate-sensitive assets. The Dow snapped a three-session winning streak, while broad-market ETFs and small caps declined. Housing also remained a concern after July, as new-home sales fell 10.5% while mortgage rates remained elevated near 6.7%.
NVIDIA delivered another record quarter, with revenue of $96.2 billion, up 106% year over year, led by $89 billion in data-center sales. Its $108 billion third-quarter revenue outlook exceeded Wall Street expectations, but shares slipped in extended trading as investors weighed AI-spending sustainability and long-term competitive risks.
After the bell, enterprise software and cybersecurity earnings lifted several technology names. Salesforce topped expectations, raised its full-year outlook, and expanded its Anthropic partnership, sending shares sharply higher. Okta also rallied after beating estimates and lifting guidance as demand for identity security tied to agentic AI strengthened, while CrowdStrike rose after topping earnings and revenue expectations. HP raised its full-year EPS and free-cash-flow outlook after third-quarter revenue climbed 12.5%, and Synopsys increased its full-year forecast following strong quarterly results. Featured: Why Trump really wants Greenland (Ad) 
| Consumer Discretionary | |
Williams-Sonoma’s (NYSE: WSM) stock broke out of a trading range earlier this year to confirm its uptrend remains intact. The market reconfirmed the breakout following the Q2 earnings release, signaling the next leg of the uptrend is at hand. How high the stock gets depends on several factors, incl... Read the Full Story |
| From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7.
One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race. | | Get the name, ticker, and full Hotlist before markets open |
| Materials | |
The global semiconductor supply chain has a critical vulnerability that traces back to a single raw material. Used in everything from advanced military radar to next-generation artificial intelligence (AI) hardware, gallium is a critical material for modern technology. With foreign monopolies activ... Read the Full Story |
| Technology | |
The wearable technology space is quietly undergoing a structural shift. Forecasts project that the global wearables market will surpass $100 billion in 2026 and reach roughly $230 billion by 2033. Investors seeking the next wave of hardware capitalization are closely watching Oura Health.
Oura is r... Read the Full Story |
| From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
| Consumer Discretionary | |
Say what you like about Elon Musk, the man knows how to command an audience—this month brought his latest flourish, a promise that Tesla Inc. (NASDAQ: TSLA) will soon show off a hovering version of its long-awaited Roadster, using rocket-style thruster technology to lift the sports car clean off th... Read the Full Story |
| Technology | |
Photronics (NASDAQ: PLAB) is a critical cog in the AI ecosystem because of what it makes. It isn’t a semiconductor company per se, but makes photomasks, the blueprints from which nearly all semiconductors are made.
The company is tight-lipped about client details but it is understood to be well en... Read the Full Story |
| From Our Partners | | The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon.
A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years. | | See the company sitting on the biggest energy source on Earth |
| Markets | |
Before the OpenAI IPO materializes and while Anthropic has yet to go public, it may be tough for investors to cite a single company as the face of AI. Still, NVIDIA Corp. (NASDAQ: NVDA) is as good a candidate as any: as the largest publicly traded firm in the world and an undisputed leader in the s... Read the Full Story |
| Technology | |
Palantir Technologies (NASDAQ: PLTR) has become a stock behavioral psychologists would love. That's because every data point splits investors into the same two camps. The bulls believe Palantir is a rare one-of-one stock that has much more runway than the current price suggests. The bears see PLTR ... Read the Full Story |
| Technology | |
The artificial intelligence (AI) computing sector is fracturing. For years, one hardware architecture dictated the pace of AI advancement. Today, hyperscalers are rewriting that narrative by bringing silicon development in-house. Newly released benchmark results around the Hot Chips 2026 conference... Read the Full Story |
| Markets | |
With market concentration remaining near all-time highs, achieving true portfolio diversification means that today’s investors need to look beyond the major indices. That entails funds that provide exposure to international value stocks, small caps, and emerging markets.
For investors seeking broad... Read the Full Story |
| Industrials | |
In an earnings season where many companies delivered standout results, Honeywell Aerospace (NASDAQ: HONA) stood out for the wrong reasons. The company delivered its first earnings report as a stand-alone company, and the results were underwhelming.
Net income was down 70%, adjusted earnings per sh... Read the Full Story |
| Thursday's Early Bird Stock Of The Day Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts. | Should I Buy Thermo Fisher Scientific Stock? TMO Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Thermo Fisher Scientific was last updated on Thursday, August 27, 2026 at 1:05 AM.
Thermo Fisher Scientific Bull Case -
Thermo Fisher Scientific Inc. has a diverse portfolio that includes analytical instruments and laboratory equipment, which positions the company well in the growing life sciences market.
-
The company is actively involved in biopharma services, including contract development and manufacturing, which is crucial for pharmaceutical and biotechnology companies looking to streamline their operations.
-
Recent advancements in their laboratory information management and data-analysis software enhance operational efficiency for clients, making Thermo Fisher a valuable partner in research and clinical settings.
-
The current stock price of Thermo Fisher Scientific Inc. is competitive, reflecting strong market confidence and potential for growth in the healthcare sector.
-
With a focus on specialty diagnostics and life sciences reagents, the company is well-positioned to capitalize on increasing demand for innovative healthcare solutions.
Thermo Fisher Scientific Bear Case -
Market competition in the analytical instruments and laboratory equipment sector is intense, which could pressure profit margins and market share.
-
Dependence on the pharmaceutical and biotechnology sectors means that any downturn in these industries could adversely affect Thermo Fisher's revenue streams.
-
Regulatory challenges in the healthcare industry can lead to increased operational costs and delays in product development, impacting overall performance.
-
Fluctuations in demand for laboratory consumables can create volatility in sales, making revenue projections less predictable.
-
Investors may be concerned about the company's ability to innovate and keep pace with rapid technological advancements in the life sciences field.
| | View Today's Stock Pick |
|
| |
|
|
